U-PRESID CHINA Reports 2025 Profit Attributable to Shareholders of RMB 2.05 Billion, Up 10.88%, Declares Final Dividend

Stock News03-05 10:49

Significant corporate developments include: Binhai Investment (02886) received additional investment from Tianjin TEDA and Sinopec to deepen its natural gas and clean energy footprint. Jinxin Fertility (01951) commenced trial operations at the new campus of its Shenzhen Zhongshan Maternity Hospital, with oocyte retrieval cycles increasing 18% year-on-year in the first two months and approximately 38% growth in the United States. CSPC Pharmaceutical Group (01093) announced that its Emicizumab injection (SYS 6053) received clinical trial approval in China. Hengrui Pharmaceuticals (01276) reported that its injectable SHR-A2102 and SHR-8068 injection obtained drug clinical trial approval notices. A subsidiary of Hengrui Pharmaceuticals (01276) also received a clinical trial approval notice for its drug HRS-1780 tablets. HUTCHMED (00013) initiated a global study for its PI3K/PIKK-EGFR ATTC candidate drug HMPL-A580 for the treatment of solid tumors. CanSino Biologics-B (02627) announced that its mRNA monkeypox vaccine received许可 from the US FDA.

Regarding financial results: U-PRESID CHINA (00220) released its annual performance, reporting a profit attributable to shareholders of RMB 2.05 billion, an increase of 10.88% year-on-year, and declared a final dividend of RMB 0.4747 per share. Qingci Games (06633) issued a profit alert, expecting its net profit for the 2025 fiscal year to increase by approximately 134% to 197% year-on-year. West China Cement (02233) also issued a profit alert, forecasting that profit attributable to shareholders for the 2025 fiscal year will increase by about 33% to 43%. Chizicheng Technology (09911) projected its 2025 profit attributable to shareholders to be between RMB 900 million and RMB 940 million, representing growth of approximately 87.5% to 95.8%. Zhouheiya (01458) anticipated its 2025 profit to be in the range of RMB 150 million to RMB 165 million, a year-on-year increase of about 52.7% to 68.0%. China Power (02380) reported a total consolidated electricity sales volume of 10.4595 million megawatt-hours for January, up 4.79% compared to the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment